Certain identified information has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. Information that was omitted has been noted in this document with a placeholder...Commercialization Agreement • July 23rd, 2021 • Calliditas Therapeutics AB • Pharmaceutical preparations • England and Wales
This COMMERCIALIZATION AGREEMENT (this “Agreement”) is made and effective as of July 21, 2021 (the “Effective Date”) by and among Calliditas Therapeutics AB, a company organized under the laws of Sweden, with company registration number 556659-9766 and its registered office and mailing address at PO Box 70351, SE-107 24 Stockholm, Sweden and its principal office and address for courier delivery at Kungsbron 1, C8, SE-111 22 Stockholm, Sweden (“Calliditas”) and STADA Arzneimittel AG, a company organized under the laws of Germany, with a registered office at Stadastrasse 2-18, 61118 Bad Vilbel, Germany (“Partner”) (each of Calliditas and Partner being a “Party,” and collectively, the “Parties”).
